Tapentadol immediate-release

Drug Profile

Tapentadol immediate-release

Alternative Names: BN-200; CG-5503; Nucynta; Palexia; R-331333; Tapentadol HCl immediate release; Tapentadol hydrochloride; Tapentadol IR; Tapentadol OS

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Grunenthal
  • Developer Grunenthal; Janssen Research & Development; Ortho-McNeil
  • Class Opioid analgesics; Phenols; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Phase III Postoperative pain

Most Recent Events

  • 05 Dec 2017 Collegium Pharmaceuticals will commercialise tapentadol in USA from 2018 onwards
  • 12 Jan 2017 Grunenthal terminates a phase II trial in Postoperative pain (In infants, In neonates) in USA, Poland and United Kingdom (PO) (NCT02221674)
  • 12 Jan 2017 Janssen suspends a phase III trial in Postoperative pain (In adolescents, In children, In infants, In neonates) in United Kingdom, Austria, Germany, USA, Bulgaria, Croatia, Czech Republic, France, Hungary, Poland, Puerto Rico and Spain for patients aged six months and older (PO) (NCT02081391)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top